CHAPEL HILL, N.C.–Crown Marketing (OTCQB: CWNM) is pleased to announce that its subsidiary, Crown Nutraceuticals has issued a one million dollar purchase order with media firm Rhodium Inc. Rhodium, a full scale global agency, with over 1.3 billion impressions since 2011, will be coordinating Crown’s Nutraceuticals campaign for its diet products featuring Raspberry Ketone and Green Bean Coffee Extract. These two popular supplements are widely recognized to be safe and effective treatments for weight loss. Crown anticipates positive revenue growth as a result of this aggressive marketing campaign. (more…)

RALEIGH, N.C.– BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI’s recent achievements and an update on business operations and upcoming milestones for 2013. (more…)

CARY, NC–Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, today announced it has entered into an agreement with Digestive Care, Inc. (DCI) to acquire exclusive U.S. rights to market PERTZYE® (pancrelipase) for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF). PERTZYE is a unique pancreatic enzyme product and is protected by several U.S. patents1. The PERTZYE formulation was previously marketed by DCI for more than a decade under the trade name PANCRECARB® MS-16. It is estimated that about 90% of patients with CF receive pancreatic enzyme replacement therapy (PERT)2 with the therapeutic category experiencing 24% annual growth from 2008-2012. (more…)

RALEIGH, N.C.–BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2013 Health Care Conference.  The presentation is scheduled for Tuesday, May 14, 2013 at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time), at the Encore at Wynn in Las Vegas, Nevada. (more…)

RALEIGH, N.C.–BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2012 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI’s 2012 achievements and an update on business operations and upcoming milestones for 2013. In 2012, significant progress was made in the development of BDSI’s two buprenorphine-containing products with the initiation, in partnership with Endo Health Solutions (Endo), of two Phase 3 pivotal trials with BEMA Buprenorphine for the treatment of chronic pain.  BDSI also completed key bioavailability and safety studies with BUNAVAIL (formerly BEMA Buprenorphine/Naloxone or BNX) for the treatment of opioid dependence.  (more…)

MORRISVILLE, N.C.–Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, announced today that June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex, is scheduled to present at the Cowen 33rd Annual Healthcare Conference in Boston, MA on Monday, March 4, 2013 at 2:10 p.m. ET. Dr. Almenoff will provide a corporate overview and discuss Furiex’s therapeutic pipeline. (more…)

CARY, N.C.–Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the “Company”) announced today that its Board of Directors has received a letter from Chiesi Farmaceutici SpA (”Chiesi”). In that letter Chiesi, which owns approximately 60% of the outstanding shares of the Company’s common stock, made a proposal, subject to certain conditions, to acquire the shares of the Company’s common stock that it does not already own for a cash purchase price of between $6.40 and $6.70 per share. (more…)

RESEARCH TRIANGLE PARK, N.C.–Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction to maximize value to its stockholders. (more…)

MORRISVILLE, N.C.–Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Under its agreement with Takeda, Furiex is entitled to receive a $25 million milestone payment as a result of this approval, as well as royalties on sales in the United States and potential sales-based milestones. Furiex has already been receiving royalty payments from Takeda for the sale of NESINA and LIOVEL in Japan. (more…)

RALEIGH, N.C.–BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the completion of its study evaluating the safety and tolerability of BEMA Buprenorphine/Naloxone (BNX) in the treatment of opioid dependent patients. (more…)

MORRISVILLE, N.C.–Vestiq Pharmaceuticals, an emerging Specialty Pharmaceutical Company, formally announces its launch of products that began commercialization in December of 2012. Vestiq is strategically formed through a consolidation of existing U.S. and international pharmaceutical entities and industry partnerships. The Company’s headquarters are located near Research Triangle Park, N.C., and the company’s website is www.vestiqpharma.com. (more…)

RESEARCH TRIANGLE PARK, N.C.–Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer. “Dave has provided meaningful contributions and leadership since joining Tranzyme said Vipin Garg, PhD, Tranzyme’s President and Chief Executive Officer. I look forward to working with him in his new role as we continue to advance the Company.” Mr. Moore joined Tranzyme in August 2011 from Johnson & Johnson as Vice President, Commercial Operations and his responsibilities were increased in January 2012 to include the oversight of Business Development. (more…)